Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3378.

https://doi.org/10.1182/blood-2023-182388

Published: 2023

Journal Articles

Real-World Evaluation of Outcomes in Relapsed/Refractory Multiple Myeloma Patients That Are Triple-Class Exposed after Receiving 2 or More Prior Lines of Therapy

Katherine Radwanski, Junhua Yu, Kody Pierce, Chetasi Talati, Steve Stricker, Shiyin Jiao, Orlando Bueno

Blood (2023) 142 (Supplement 1): 3358.

https://doi.org/10.1182/blood-2023-178824

Published: 2023

Journal Articles

Pharmacokinetics and Immunogenicity of Abbv-383, a B-Cell Maturation Antigen (BCMA) × CD3 Bispecific T-Cell-Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Akshanth R Polepally, Carla Biesdorf, Muhammad Erfan Uddin, Nils Boehm, Jeremy A Ross, Shaji Kunnathu Kumar, Peter M. Voorhees, Anita D'Souza, Katja Weisel, Orlando Bueno, Chetasi Talati, Rajeev M Menon

Blood (2023) 142 (Supplement 1): 6722.

https://doi.org/10.1182/blood-2023-180127

Published: 2023

Journal Articles

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

Amanda Przespolewski, Aaron D. Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani, Srinivasa R. Sanikommu, Swapna Thota, Julian Waksal, Brian Ball, Christopher Famulare, Maximilian Stahl, Jeffrey Baron, Elizabeth A. Griffiths, James E. Thompson, Kendra Sweet, Eunice S. Wang

Blood (2023) 141 (12): 1489–1493.

https://doi.org/10.1182/blood.2022016678

Published: 2023

Includes: Supplemental data

Journal Articles

A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 4401–4404.

https://doi.org/10.1182/blood-2022-167008

Published: 2022

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies

Blood (2022) 140 (Supplement 1): 10542–10544.

https://doi.org/10.1182/blood-2022-167098

Published: 2022

Journal Articles

The Long Non-Coding RNA MALAT1 Is Necessary for Hematopoietic Stem and Progenitor Cell Expansion and Preleukemic Myeloproliferation in TET2 Deficient Myeloid Neoplasms

Nana Adjoa Ben-Crentsil, Ariel Quintana-Gonzalez, Maria E Balasis, Hannah Newman, Traci L. Kruer, Lei Sun, Christopher Letson, Abhishek Dhawan, Chetasi Talati, Meghan Ferrall-Fairbanks, Alexis Vedder, Kathy McGraw, Rami S. Komrokji, Li Ma, Eric Padron

Blood (2022) 140 (Supplement 1): 1991–1993.

https://doi.org/10.1182/blood-2022-156670

Published: 2022

Journal Articles

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Blood (2022) 140 (Supplement 1): 3419–3421.

https://doi.org/10.1182/blood-2022-165802

Published: 2022

Journal Articles

Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance)

Blood (2021) 138 (Supplement 1): 226.

https://doi.org/10.1182/blood-2021-152838

Published: 2021

Journal Articles

Mutations Highly Specific for Secondary AML Are Associated with Poor Outcomes in Patients with NPM1 -Mutated ELN Favorable Risk AML

Onyee Chan, Najla Al Ali, Hammad Tashkandi, Austin Ellis, Somedeb Ball, Ling Zhang, Mohammad Hussaini, Jinming Song, Seongseok Yun, Chetasi Talati, Andrew T. Kuykendall, Eric Padron, David A. Sallman, Kendra Sweet, Rami S. Komrokji, Jeffrey E. Lancet

Blood (2021) 138 (Supplement 1): 686.

https://doi.org/10.1182/blood-2021-150759

Published: 2021

Journal Articles

Comparative Effectiveness of Venetoclax Combinations Vs Other Therapies Among Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from the AML Real World Evidence (ARC) Initiative

Blood (2021) 138 (Supplement 1): 2328.

https://doi.org/10.1182/blood-2021-151285

Published: 2021

Journal Articles

High MYC Expression Predicts Poor Survival Outcomes in IDH1/2 Mutant AML Patients

Virginia Olivia Volpe, Nicole D. Vincelette, Onyee Chan, Chetasi Talati, Kendra Sweet, Andrew T. Kuykendall, Constantine Logothetis, Rami S. Komrokji, Gregoire Calon, Nathan P. Horvat, David A. Sallman, Eric Padron, Ling Zhang, Seongseok Yun

Blood (2021) 138 (Supplement 1): 2377.

https://doi.org/10.1182/blood-2021-147030

Published: 2021

Journal Articles

Comparison of Liposomal Daunorubicin and Cytarabine Versus Cladribine and High-Dose Cytarabine-Based Induction Chemotherapy in Secondary Acute Myeloid Leukemia Patients (sAML) or Acute Myeloid Leukemia with Myelodysplastic Related Changes (AML-MRC)

Ariel Denson, Ryan J. Caddell, Katherine A. Richter, Jiannong Li, Kendra Sweet, Andrew T. Kuykendall, Eric Padron, Rami S. Komrokji, Jeffrey E. Lancet, Chetasi Talati, David A. Sallman

Blood (2021) 138 (Supplement 1): 1258.

https://doi.org/10.1182/blood-2021-151303

Published: 2021

Journal Articles

Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis

Amanda Przespolewski, Aaron D Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani, Srinivasa Reddy R. Sanikommu, Swapna Thota, Julian Waksal, Brian Ball, Christopher Famulare, Maximilian Stahl, Zoe Mckinnell, Jeffrey Baron, Elizabeth A. Griffiths, James E. Thompson, Kendra Sweet, Eunice S. Wang

Blood (2021) 138 (Supplement 1): 1264.

https://doi.org/10.1182/blood-2021-153791

Published: 2021

Journal Articles

Real-World Management of Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax-Based Regimens: Results from the AML Real World Evidence (ARC) Initiative

Blood (2021) 138 (Supplement 1): 1271.

https://doi.org/10.1182/blood-2021-151586

Published: 2021

Journal Articles

Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

David A. Sallman, Hany Elmariah, Kendra Sweet, Chetasi Talati, Asmita Mishra, Cheryl A Cox, Roshanak Semnani, Rutul R Shah, Helen Sabzevari, Marion Chakiath, Justin Uthuppan, Amy Lankford, Chen Wang, Eric Padron, Andrew T. Kuykendall, Rami S. Komrokji, Jeffrey E. Lancet, Marco L. Davila, Nelli Bejanyan

Blood (2021) 138 (Supplement 1): 825.

https://doi.org/10.1182/blood-2021-152692

Published: 2021

Journal Articles

Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies

Quinto J Gesiotto, MD, David M Swoboda, MD, Najla E. Al Ali, Eric Padron, MD, Andrew T. Kuykendall, MD, Jinming Song, MD PhD, Chetasi Talati, MD, Kendra L. Sweet, MD MS, Jeffrey E. Lancet, MD, Rami Komrokji, MD, David A. Sallman, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140861

Published: 2020

Journal Articles

Characteristics of Different Splicing Factor Mutation Hotspots in Myelofibrosis

Franco Castillo Tokumori, MD, Chetasi Talati, MD, Najla E. Al Ali, David A. Sallman, MD, Seongseok Yun, MDPhD, Kendra L. Sweet, MD MS, Eric Padron, MD, Jeffrey E. Lancet, MD, Rami Komrokji, MD, Andrew T. Kuykendall, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-140145

Published: 2020

Journal Articles

Acquisition of IDH2 Mutations in Relapsed/Refractory AML Is Associated with Worse Patient Outcomes

Amy Song, Omar Altabbakh, BS, David A. Sallman, MD, Eric Padron, MD, Chetasi Talati, MD, Mohammad O Hussaini, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-142615

Published: 2020

Journal Articles

A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Guillermo Garcia-Manero, MD, Uwe Platzbecker, Stefano R. Tarantolo, MD, Stefanie Gropper, Chetasi Talati, MD, Katharina S. Götze, James Dugan, MD, Eric S. Winer, MD, Elizabeth Martinez, PhD DHSC, MSN, Christopher Lieberman, Reinhard von Roemeling, MD

Blood (2020) 136 (Supplement 1): 16.

https://doi.org/10.1182/blood-2020-140889

Published: 2020

NARROW

Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma

Real-World Evaluation of Outcomes in Relapsed/Refractory Multiple Myeloma Patients That Are Triple-Class Exposed after Receiving 2 or More Prior Lines of Therapy

Pharmacokinetics and Immunogenicity of Abbv-383, a B-Cell Maturation Antigen (BCMA) × CD3 Bispecific T-Cell-Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies

The Long Non-Coding RNA MALAT1 Is Necessary for Hematopoietic Stem and Progenitor Cell Expansion and Preleukemic Myeloproliferation in TET2 Deficient Myeloid Neoplasms

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance)

Mutations Highly Specific for Secondary AML Are Associated with Poor Outcomes in Patients with NPM1 -Mutated ELN Favorable Risk AML

Comparative Effectiveness of Venetoclax Combinations Vs Other Therapies Among Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from the AML Real World Evidence (ARC) Initiative

High MYC Expression Predicts Poor Survival Outcomes in IDH1/2 Mutant AML Patients

Comparison of Liposomal Daunorubicin and Cytarabine Versus Cladribine and High-Dose Cytarabine-Based Induction Chemotherapy in Secondary Acute Myeloid Leukemia Patients (sAML) or Acute Myeloid Leukemia with Myelodysplastic Related Changes (AML-MRC)

Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis

Real-World Management of Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax-Based Regimens: Results from the AML Real World Evidence (ARC) Initiative

Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies

Characteristics of Different Splicing Factor Mutation Hotspots in Myelofibrosis

Acquisition of IDH2 Mutations in Relapsed/Refractory AML Is Associated with Worse Patient Outcomes

A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only